(MENAFN- GlobeNewsWire - Nasdaq) Emerging opportunities in the Graves' Disease market include advancing novel drugs such as Batoclimab and BHV-1300, enhancing therapeutic options. Companies like Immunovant and Biohaven are pivotal players. The focus is on innovative treatments targeting autoimmune pathways, with potential in related disorders.

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Graves' Disease - Pipeline Insight, 2025" has been added to ResearchAndMarkets's offering.

The "Graves' Disease - Pipeline Insight, 2025" report offers a detailed analysis of the Graves' Disease landscape, featuring insights into 8+ companies and 10+ pipeline drugs. The report covers drug profiles at various developmental stages, evaluating them by product type, stage, administration route, and molecular structure. It also highlights inactive pipeline products.

Graves' disease is an autoimmune condition and the leading cause of hyperthyroidism in the U.S., predominantly affecting women. It is caused by antibodies that overstimulate the thyroid, leading to excessive hormone production. This imbalance can cause significant health issues, including an enlarged thyroid (goiter) and potential eye problems.

Certain factors elevate the risk of developing Graves' disease, including genetic predisposition, gender (more common in women), age (typically under 40), other autoimmune diseases, stress, and smoking. Diagnosis involves clinical evaluation and lab tests that indicate elevated levels of thyroid hormones and the presence of specific antibodies.

The report provides a comprehensive overview of the current and future treatments, offering a detailed picture of the pipeline landscape. This includes a commercial and clinical assessment of developmental drugs, describing their mechanisms, clinical studies, approvals, and other development activities. Treatment strategies aim to manage hyperthyroidism and symptoms, utilizing antithyroid medications, radioactive iodine therapy, or surgery. Options also include beta-blockers and, for those with eye complications, steroids, radiation, or surgery.

Report Highlights: The report details the efforts of companies and academic institutions to overcome challenges in Graves' Disease R&D, emphasizing new treatment approaches.

Graves Disease Emerging Drugs and Developments: The report includes a detailed analysis of drugs in clinical stages from Phase I to III, alongside preclinical studies. It covers clinical trial details, pharmacological actions, and latest updates.

Key Developments Include:

Batoclimab (Immunovant Sciences GmbH): A Phase III development, this fully human monoclonal antibody targets the FcRn receptor, reducing IgG antibodies through subcutaneous injections. It holds promise for managing various IgG-mediated autoimmune conditions.
BHV-1300 (Biohaven Therapeutics Ltd.): Utilizing the MoDET platform, BHV-1300 specifically degrades certain IgG antibodies while sparing others, showing potential across autoimmune diseases like Graves' disease, currently in Phase I.

Therapeutic Assessment: The report breaks down Graves' Disease drugs by parameters such as development phase, route of administration, and molecule type, providing a rich assessment of ongoing pipeline activities. Categories include monoclonal antibodies, small molecules, and peptides available in various formats like intravenous or oral.

The report elucidates the dynamics in the Graves' Disease therapeutic arena, with insights into collaborations, acquisitions, licensing, and unmet needs. It aims to provide thorough pipeline analysis and assessment of emerging drugs, considering their potential impact on current treatment paradigms.

• Key Players: Immunovant Sciences GmbH, Sanofi, Biohaven Therapeutics Ltd., Septerna Corporation.
• Key Products: Batoclimab, Rilzabrutinib, BHV-1300, TSHR Program.

Key Topics Covered:
Introduction
Executive Summary
Graves' Disease: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Graves' Disease - Analytical Perspective
Late Stage Products (Phase III)

• Comparative Analysis

Mid Stage Products (Phase II)

• Comparative Analysis

Early Stage Products (Phase I)

• Comparative Analysis

Preclinical and Discovery Stage Products

• Comparative Analysis

Inactive Products

• Comparative Analysis

Graves' Disease Key Companies
Graves' Disease Key Products
Graves' Disease - Unmet Needs
Graves' Disease - Market Drivers and Barriers
Graves' Disease - Future Perspectives and Conclusion
Graves' Disease Analyst Views
Graves' Disease Key Companies

• Immunovant Sciences GmbH
• Sanofi
• Biohaven Therapeutics Ltd.
• Septerna Corporation

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN22102025004107003653ID1110231581